China-based SciClone Pharmaceuticals Inc. announced a licensing agreement with Eisai Co., Ltd (TYO: 4523), securing exclusive development and commercialization rights to the Japanese firm’s tasurgratinib succinate (E7090) in China.
Drug Profile
Tasurgratinib, an orally available selective inhibitor of FGFR 1-3, was approved in Japan in September of last year. It is used to treat unresectable biliary tract cancer patients carrying FGFR2 gene fusion or rearrangement who have progressed after chemotherapy, under the trade name Tasfygo.
Agreement Terms
Under the agreement, SciClone will be responsible for the development and commercialization of tasurgratinib in China. In return, the company will pay Eisai an undisclosed upfront payment and is committed to making certain development, regulatory, and marketing milestone payments, as well as royalties.-Fineline Info & Tech
Leave a Reply